Compare SLNG & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ASRT |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 75.1M |
| IPO Year | N/A | 1997 |
| Metric | SLNG | ASRT |
|---|---|---|
| Price | $5.51 | $12.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $35.00 |
| AVG Volume (30 Days) | 10.7K | ★ 70.3K |
| Earning Date | 02-24-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $72,270,000.00 | ★ $137,354,000.00 |
| Revenue This Year | $7.02 | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $104.70 | ★ N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $3.29 | $7.71 |
| 52 Week High | $8.28 | $15.15 |
| Indicator | SLNG | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 67.55 | 81.67 |
| Support Level | $4.28 | $11.08 |
| Resistance Level | $6.36 | $12.54 |
| Average True Range (ATR) | 0.38 | 0.68 |
| MACD | 0.15 | -0.12 |
| Stochastic Oscillator | 61.01 | 84.72 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.